Skip to main content
Figure 1 | Malaria Journal

Figure 1

From: Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling

Figure 1

Overview showing the original PK/PD model (black boxes), the extension to allow for region specific dosing by weight or age (green box) and the different treatment scenarios simulated (red boxes). * If artesunate or artemether are given, the model accounts for their absorption and conversion into the active metabolite dihydroartemisinin (DHA). The model then updates parasite numbers in the next time step using only the drug with the larger effect, i.e. either the parent drug or DHA.

Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us